Rusfertide - Protagonist Therapeutics
Alternative Names: PTG-300; Rusfertide acetate - Protagonist Therapeutics; TAK-121Latest Information Update: 04 Jun 2024
At a glance
- Originator Protagonist Therapeutics
- Class Antianaemics; Antineoplastics; Peptides
- Mechanism of Action Hepcidin replacements; Iron modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Polycythaemia vera
- Phase II Haemochromatosis
- Discontinued Beta-thalassaemia; Myelodysplastic syndromes
Most Recent Events
- 31 May 2024 Takeda anticipates target filling for Polycythemia vera in 2025 (Takeda pipeline, May 2024)
- 31 Jan 2024 Protagonist Therapeutics and Takeda enters into a license and collaboration agreement for the development and commercialization of rusfertide
- 22 Jan 2024 Phase-III clinical trials in Polycythaemia vera (Treatment-experienced) in USA (SC) (NCT06033586)